Page 5 - The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews

Curr Neurol Neurosci Rep (2018) 18:8 Page 5 of 12 8

AMSTAR score 2 10 4 6 3 5

Funding/COIs reported Not Declared funding/no COI apparent funding Declared no with COI apparent No funding/- COI possible reported/no Not COI apparent funding No

SIGN grade 1− 1+ 1− 1+ 1− 1−

Year studies published 2003–2010 2003–2010 1987–2012 2004–2013 2002–2006 1981–2009

review, n =57 and [Clifford parallel one 2004) [n = 189], Collin 2010 Van 2004 Zajicek 2002 2004 Vaney [n = 135], [n = 160], [n = 522], [n = 66], [n = 502], 2004 (Killestein 2009 RCT (Rog 2004 Zajicek (n =255), (n = 20), placebo-controlled 1981 Martyn Zajicek Wade Rog 2007 Rog 2009

the 2004] (n = 8 double-blind and Wade [n = 339], RCT Killestein 2004 2006 2005 2005 [n = 20]), Randomised (Centzone post RCTs [n = 160], RCT (Svendsen (n =16), and experimental Ellenberger (n = 16), (n =24), (n =502), (n = 13), Conte
by [Fox series 2010) n = 667 Wade [n =657], [n = 37], [n = 43], 2010 Wade Freeman Rog Zajicek Svendsen follow-up 2005 2003 included and (n =13), 2002 2005 (n = 189),
considered reported^ Two randomised, double-blind placebo-controlled (n = 14 case one randomised Collin (1, 2013 2003 crossover or 2012 2014 (Kavia [n = 630], [n = 224], [n = 265], [n = 37], 1994 2002 [n = 16], Collin 2010 [n = 337], Fox 2004 [n = 15]) double-blind controlled trial (Ungerleider 1987 study label label [n =137]) placebo-controlled 2004 Wade crossover 2002 Killestein Freeman Wade (n = 15) (n =34), we obser

evidence size study 2004]), one n = 337 (1, RCT Parallel RCT (Collin 2007 Langford Amerongen2014[n = 24], Zajicek [n = 279]) Leocani RCTs 2003 Vaney2004[n = 57], 2012 2010 Greenberg 2002 Fox Open Open 2006 [n = 66], trials: [n = 630], 2005 2004 trials, clinical non-randomised, in (RCTs) RCT: Ungerleider (n = 1), (n = 630), (n = 57), (n = 66), Collin

of sample crossover [Vaney 1983]), group double-blind [n = 337], [n = 160], 2012 (Corey-Bloom [n = 16], [n =57]) Double-blind Zajicek Zajicek Collin Corey-Bloom [n = 24], [n = 14], [n = 13]); [n = 20]), (Wade Double-blind 2005 Double-blind [n =24]) 2003 Brady Notcutt the randomised, settings. (n = 9), 1995 2003 2004 2005 (n = 63),
Types and and Clinical and For of trials

cannabinoids disorders. the of management non-spastic paininMSpatients. controls healthy data relevant properties already or settings.

exogenous movement review of events To determine the efficacy of medical marijuana in conditions. pain of reduction neuralgic To examine the randomised and crossover studies to CBD and current antinociceptive potential their clinical

of of systematic adverse review the the for in
use treatment neurologic for patients. most use
review the a and cannabinoids. systematically non-trigeminal that administered the on cannabinoids

of assess the conduct benefits several strategies clinical review available established
Aim To in To To To

of Type review Systematic review Systematic review Systematic review Systematic review Systematic review Systematic review
characteristics a of clinical of in of pain MS in pain spasticity

reviews the in of disorders: review and series Cannabinoids for medical systematic and review: safety and marijuana neurologic review pharmacological in Cannabidiol in humans— for targets cannabinoids of treatment

of Cannabinoids treatment movement systematic case trials a use: review meta-analysis Systematic efficacy medical selected disorders systematic management quest the therapeutic of the and (painful)
Overview Title A Role

ID 2015 2014 2013
1 Andrzejewski 2016 Zhornitsky 2012 2010
Table Review Whiting Koppel Jawahar Karst